Skip to content
Open access

METTL3-mediated m6A modification of RBM39 promotes cancer stemness and tumor progression in head and neck squamous cell carcinoma

Sep 2026 · Discover Oncology · 0 citations

TL;DR

Pan-cancer analysis showed that RBM39 is aberrantly expressed in multiple cancers and is significantly associated with patient prognosis, suggesting its diagnostic value, and RBM39 may serve as a potential diagnostic and therapeutic target for HNSC.

Abstract

RBM39 plays an important regulatory role in multiple cancers. However, its systematic function across pan-cancer and its specific mechanism in head and neck squamous cell carcinoma (HNSC) remain unclear. In this study, we performed pan-cancer expression and survival analyses based on TCGA and GTEx databases, combined with copy number variation and DNA methylation analyses to explore the regulatory mechanisms of RBM39. GSEA and functional enrichment were used to identify associated signaling pathways. In HNSC cells, qRT-PCR, CCK-8, Transwell, and tumor sphere formation assays were performed to validate its biological functions. In addition, RM2Target and SRAMP databases were used to investigate m 6 A-mediated regulation of RBM39, and RNA stability assays were performed for validation. The relationship between RBM39 and tumor immune infiltration as well as drug sensitivity was also evaluated. Pan-cancer analysis showed that RBM39 is aberrantly expressed in multiple cancers and is significantly associated with patient prognosis, suggesting its diagnostic value. In HNSC, RBM39 is significantly upregulated and positively correlated with tumor stage. In vitro experiments demonstrated that RBM39 knockdown significantly inhibited tumor cell proliferation and migration. Mechanistically, RBM39 activates the Wnt signaling pathway and upregulates key target genes, including CTNNB1, SOX2, OCT4, and MYC, thereby promoting cancer stem cell self-renewal. Furthermore, METTL3-mediated m 6 A modification enhances RBM39 mRNA stability and increases its expression. RBM39 acts as a key oncogenic factor in HNSC by promoting tumor progression and stemness through an m 6 A-dependent mechanism and Wnt pathway activation. It also contributes to an immunosuppressive microenvironment and drug resistance. RBM39 may serve as a potential diagnostic and therapeutic target for HNSC.

Read PDF

Similar papers

Open access Oct 2026

Pan-cancer and experimental analyses reveal TTC39B as a suppressor of cell proliferation in clear cell renal cell carcinoma

Tetratricopeptide repeat domain protein 39B (TTC39B) is a lipid metabolism–related gene recently implicated in cholesterol regulation. However, its clinical and biological relevance in human cancers remains undefined. Based on multi-omics data from the Cancer Genome Atlas (TCGA) pan-cancer dataset represen...

Hui-Juan Yi, Yan Wang, Chen-Hao Zhao et al. · 0 citations
Open access Sep 2026

HIST1H4L promotes small cell lung cancer tumorigenesis by regulating the PI3K/Akt pathway and serves as a potential diagnostic biomarker

HIST1H4L was significantly upregulated in SCLC tumors versus normal tissues and enriched in DNA transcription-related pathways and correlated with poor patient survival; critically, high HIST1H4L expression correlated with poor patient survival.

Shi-Cheng Feng, Min Feng, Zhi-Qiang Lu et al. · 0 citations
Open access Sep 2026

Integrated multi-omics analyses reveal the role of PAXX in colorectal cancer progression and the tumor immune microenvironment

Functional and rescue experiments support MAPK/ERK signaling as a partial mediator of PAXX-associated malignant phenotypes and EMT-related alterations in CRC progression and its association with the tumor immune microenvironment.

Jin-Zhong Cao, Zi-Jing Wang, Xi Luo et al. · 0 citations
Sep 2026

Abstract A068: Downregulation of MEIS2 in Multiple Cancers and Its Correlation with Improved Overall Survival: A Potential Prognostic Biomarker

The homeobox transcription factor MEIS2 is a crucial regulator of developmental processes, including embryogenesis and neurogenesis. However, its role in cancer progression and prognosis remains poorly understood across various human malignancies. This study evaluated the expression profile of MEIS2 in different canc...

Abdulrahman E. Algarni · 0 citations
Open access Sep 2026

m5C Reader ALYREF Promotes the Progression of Endometrial Cancer by Activating the XRCC6‐Mediated Wnt/β‐catenin Signaling Pathway

ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...

Lin-Lin Hao, Jian Zhang, Qi Qian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.